Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurofibromatosis 1: early-phase trial registry
12 of 25 indexed Neurofibromatosis 1 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #652 of 28,707 conditions by registered trial count.
25 US clinical trials · 12 currently recruiting · #652 of 28,707 conditions by registered trial count
Neurofibromatosis 1: 25 US clinical trials tracked, 12 recruiting.
Neurofibromatosis 1 is the subject of 25 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 5 of these trials.
Enrollment posture brief
Registry condition neurofibromatosis-1
OPEN 12 | RECR 48% | LATE 1 | EARLY 11 | RANK #652 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Diabetes Type 2 (48% recruiting · 25 trials)
Neurofibromatosis 1 lists 12 open slots (48% of 25 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurofibromatosis 1 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurofibromatosis 1 is recruiting above its size-band peers.
12 of 25 indexed trials (48%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neurofibromatosis 1 research.
National Cancer Institute (NCI) accounts for 5 of 25 trials (20%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Neurofibromatosis 1 enrolment sits around 80 participants.
Median target enrolment is 80 among the 25 trials that report a genuine target (sentinel values excluded). 14 of those (56%) plan for fewer than 100 participants.
-
Neurofibromatosis 1 splits between interventional and observational designs.
16 interventional and 9 observational studies make up this index (64% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
25 total, page 1 of 1
Neurofibromatosis (NF) Registry Portal
The Children's Tumor Foundation
NCT01885767
Neurofibromatosis Type 1 Tumor Early Detection Study
David Miller
NCT06515860
RASopathy Biorepository
Children's Hospital Medical Center, Cincinnati
NCT04395495
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Cancer Institute (NCI)
NCT02544022
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
Massachusetts General Hospital
NCT06262113
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
National Cancer Institute (NCI)
NCT06222203
Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1
University of Alabama at Birmingham
NCT06188741
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial
National Cancer Institute (NCI)
NCT05361811
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
NCT05849662
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
National Cancer Institute (NCI)
NCT04750928
Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy
Massachusetts General Hospital
NCT07233408
Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II
Donald Basel
NCT02728388
Natural History Study of Cutaneous Neurofibromas in People With NF1
Johns Hopkins University
NCT05581511
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co.
NCT04954001
Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
AstraZeneca
NCT04924608
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Cancer Institute (NCI)
NCT01362803
Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1
Johns Hopkins University
NCT05677594
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1
Children's Hospital Medical Center, Cincinnati
NCT04481048
NF-1, Nutraceutical Intervention
Masonic Cancer Center, University of Minnesota
NCT05363267
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Children's National Research Institute
NCT03820778
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics
NCT05005845
Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1
University of Arkansas
NCT05912400
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
UNC Lineberger Comprehensive Cancer Center
NCT01800032
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
NCT06120036
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
NCT06132165
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurofibromatosis 1 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurofibromatosis 1 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurofibromatosis 1 page
25 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Neurofibromatosis 1 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neurofibromatosis 1 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurofibromatosis 1 condition card totals 25 registered trials; most-linked intervention Selumetinib; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.